From PR Newswire release
Dirucotide, an IV-administered drug designed to treat patients with secondary-progressive M.S., has been given “fast track” status by the FDA, according to its manufacturer (BioMS Medical Corp). The drug is currently being studies in four late-stage clinical trials, one of which is a Phase-III study in the United States. The “fast track” designation can, potentially, speed the development and FDA review processes.
Leave a Comment » | 
Drug trials | Tagged: bioms medical corp, dirucotide, M.S., Multiple Sclerosis | 
Permalink
Posted by travelgimp
From Resarch and Markets
Want to invest in a market beleived to currently be worth 8-Billion dollars and predicted to grow at more than 10% a year? Take a look at the companies that are researching new MS drugs. That’s encouraging news for MS patients, as well as investors!
Leave a Comment » | Drug Treatments | Tagged: drug research, investments, ms drugs, ms research, Multiple Sclerosis, pharmaceutical research | Permalink
Posted by travelgimp
